Healthon Review

Our assessment

Healthon does two things well and one thing badly. It names its founder as a board-certified physician on the same page that carries the prices, and it prints the prepaid quarterly total beside each per-month figure so you can check the division, which holds. What it also does is advertise the same weight-loss program at two different starting rates at once — one in the site-wide menu, a higher one in the page heading. It carries an FDA warning letter finding its claims about the two drugs false or misleading.

Four plans, and the math holds

The weight-loss program page prices a monthly plan and a quarterly plan for each of the two drugs. The quarterly plans are stated as a total for the quarter, and each divides cleanly by three. A prepaid total and a monthly rate are different commitments, so it helps that you can see both without doing the sum yourself.

That is more than most sellers here offer. A seller that prints only a starting figure leaves the term invisible. This one prints the term and the total, and lets you check one against the other.

The page also prices a separate custom weight-loss kit, and the site sells NAD+ and sermorelin lanes alongside. Those sit outside the two GLP-1 drugs.

Two starting rates for one program

The mega-menu at the top advertises the weight-loss program at one starting rate. The page heading, a few hundred pixels below it, advertises the same program at a higher one. Both are on screen at the same time.

Which one binds is stated nowhere. The figures attached to named plans are the ones on the page; the menu figure is a separate number the site never reconciles.

The warning letter, and what it says

FDA wrote to this company in September 2025. The letter is addressed to the founder by name and title, and states that the agency reviewed the website in August 2025. It finds the claims made about its compounded semaglutide and tirzepatide false or misleading under the misbranding provisions of the Act.

Eighty of the four hundred and twenty sellers here carry an FDA warning letter. It is disclosed here and it never moves a score or a ranking position. Most of these letters concern marketing and labeling rather than the contents of a vial, and this one is explicitly about website claims.

One practical note for anyone checking this themselves. FDA's record returns nothing for this seller's domain. Letters are indexed by entity name and by the name a company does business as, so a domain search clears every seller you point it at.

The rest of the disclosure

The founder is named as a triple board-certified physician on the priced page, and the affiliated medical group is named separately in the Terms. One hundred and twenty of the four hundred and twenty sellers here name an individual clinician.

No compounding pharmacy is named. Three hundred and twenty-six of the four hundred and twenty sellers here name none. No service-area list exists; two hundred and eighty-six of the four hundred and twenty sellers here publish none. The membership question goes unanswered on a page that prices five things; one hundred and eighty-two of the four hundred and twenty sellers here leave it unanswered too.